SBFM — Sunshine Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00- $6.57m
- -$2.72m
- $34.87m
Annual cashflow statement for Sunshine Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -2.78 | -12.4 | -26.7 | -4.51 | -5.13 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 2.16 | 10.7 | 18.3 | 0 | 0.012 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.043 | -0.109 | 3.15 | -4.42 | -7.63 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Cash from Operating Activities | -0.657 | -1.83 | -5.25 | -8.78 | -12.5 |
| Capital Expenditures | -0.001 | 0 | -0.305 | -0.788 | -1.98 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0 | 0 | -14.3 | 0.132 | -0.342 |
| Acquisition of Business | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.001 | 0 | -14.6 | -0.656 | -2.32 |
| Financing Cash Flow Items | 0 | — | 28.3 | 4.09 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1.61 | 2.9 | 39.5 | 3.43 | 9.29 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.949 | 1.06 | 19.8 | -5.53 | -6.61 |